Search - tctmd.com

Displaying 81 - 100 of 148

Sort: Relevancy | Date

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Presenter: Daizo Kawasaki

September 26, 2019

Presentation TCT 2019

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Presenter: Yoshimitsu Soga

September 26, 2019

Presentation TCT 2019

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Presenter: Yann Gouëffic

September 25, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Opinion Off Script

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

Sahil Parikh, MD

July 29, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2019

Shelley Wood

March 29, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

Advertisement

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

TCTMD’s Top 10 Most Popular Stories for March 2019

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content